By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa, marking its debut in Africa and ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...

The 2025 Q2 earnings cycle is slowly winding down, which has been resilient so far. For the 457 S&P 500 companies that have reported Q2 results as of August 13th, total earnings are up +11.6% from the ...

As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a ...

CHICAGO — New research is showing certain weight loss drugs could be linked to eye related issues. A couple studies published in the Journal of the American Medical Association looks into Ozempic, ...

Eli Lilly said it would raise drug prices in Europe to "make them lower" in U.S., though the actual impact on most patients ...

Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...